14.2.2024 07:30:01 CET | Thor Medical ASA | Inside information
The Board of Thor Medical ASA has today engaged Mr. Jasper Kurth (39) as the company’s next Chief Executive Officer.
Mr. Kurth joins Thor Medical from several positions at Bayer Pharmaceuticals, most recently as General Manager Radiology Nordics in Stockholm. Prior to that, Mr. Kurth held the following positions at Bayer Pharmaceuticals: Head of Business Operations & Strategy EMEA, Head of Sub-Region Western Europe Radiology (acting), and Chief of Staff and Head of Training Radiology Europe. Mr. Kurth has been with Bayer Pharmaceuticals since he joined Bayer’s Management Trainee Program as a young student. Mr. Kurth will join Thor Medical no later than September 1.
When Mr. Kurth assumes the position as Chief Executive Officer, Dr. Alf Bjørseth (82), will continue to support the company’s client acquisition and technical development of a production facility for thorium-based alpha emitters at Herøya, Norway as Senior Vice President & Strategic Advisor.
Ludvik Sandnes, Chairman of the Board, says: We are very pleased that we have been able to attract Jasper Kurth to lead our team and further development of our company. At Bayer Pharmaceuticals, he has obtained an outstanding experience which we are very grateful that he will now share with us.
Jasper Kurth comments: Joining Thor Medical fills me with immense excitement and anticipation. I am thrilled to be part of a team dedicated to revolutionizing healthcare and making a tangible difference in the lives of patients battling cancer. Together, we’ll push boundaries, innovate relentlessly, and forge a brighter future in the fight against this devastating disease.
The Board of Thor Medical has resolved to award Jasper Kurth 3 600 000 share options. Each share option entitles Mr. Kurth to buy one share at NOK 1.118, equal to the volume-weighted share price over the last ten trading days. 1/3 of the share options will vest 12 months after Mr. Kurth’s first day of employment, while the remaining share options will vest with 100 000 on the last day of each month following the initial vesting. The share options need to be exercised no later than five years after the initial award. The total gross benefit for exercised share options under this award shall be limited to Mr. Kurth’s total base salary of the three-year period. The award of share options is made subject to the approval of the company’s General Meeting.
A notification of the transaction in accordance with the EU Market Abuse Regulation article 19 is attached with this announcement.
Disclosure regulation
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
Contacts
Ludvik Sandnes, Chairman of the Board, +47 907 43 017
About Thor Medical ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.no.
Attachments
Download announcement as PDF.pdf
Thor Medical Primary insider notification CEO.pdf
